United States v. Quality Formulation Laboratories, Inc.

512 F. App'x 237
CourtCourt of Appeals for the Third Circuit
DecidedJanuary 25, 2013
Docket11-4511, 11-4512, 11-4513
StatusUnpublished
Cited by1 cases

This text of 512 F. App'x 237 (United States v. Quality Formulation Laboratories, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Quality Formulation Laboratories, Inc., 512 F. App'x 237 (3d Cir. 2013).

Opinion

OPINION

AMBRO, Circuit Judge.

Appellants — three companies and three individuals — jointly appeal their convictions for criminal contempt and Appellants Omar and Ahmad Desoky appeal their sentences. We affirm the convictions but vacate and remand Omar and Ahmad De-soky’s sentences for further findings.

I. Background

In 2010, following a civil suit, Mohamed Desoky and the three dietary supplement companies he ran — Quality Formulations Laboratories (QFL), American Sports Nutrition (ASN), and Sports Nutrition International (SNI) — entered into a court-approved Consent Decree with the federal Food and Drug Administration (FDA) halting production at the companies’ Paterson, New Jersey manufacturing facility. The Consent Decree provided that

[QFL, ASN, SNI and Mohamed Desoky] and each and all of their officers, agents, employees, successors, and assigns, and any persons in active concert or participation with any of them who receive notice of this Decree, are permanently restrained and enjoined ... from directly or indirectly receiving, manufacturing, preparing, packing, labeling, and distributing at their plant located [in] ... Paterson, New Jersey ... or any new location(s) at which the Defendants receive, manufacture, prepare, pack, label, hold, or distribute articles of food, any article *239 of food unless and until [described] conditions have been met[.]

App. at 78, Consent Decree, para. VII. It also required that

[QFL, ASN, SNI and Mohamed Desoky] shall notify FDA in writing at least thirty (80) calendar days before any change [in] ownership, name, or character of their business, including reorganization, relocation, dissolution, assignment, or lease or sale of the business or any asset of the business, such as buildings, equipment, or inventory, that may affect compliance with the obligations arising from this Decree.

Id. at 92, Consent Decree, para. XV.

Pursuant to the Consent Decree, the Paterson facility was shut down. Subsequently, manufacture of Appellants’ products began at a facility in Congers, New York owned by ADH Health Products (“ADH”). On discovering this manufacturing, the FDA filed an order to show cause alleging criminal contempt by Mohamed, the three companies, and Mohamed’s two sons and company employees, Ahmad and Omar. The Government alleged that Appellants willfully violated the Consent Decree by manufacturing products at the Congers facility. Appellants asserted a good faith defense, arguing that they contracted with ADH to manufacture QFL products, and they believed this third-party manufacturing was permitted by the Consent Decree.

Evidence presented at trial showed that the Congers facility manufactured QFL products, that Appellants sent raw material and equipment from Paterson to Congers, that former and current QFL employees worked on the products in Congers, and that QFL paid those employees in cash. Appellants did not disclose the activities at Congers to the FDA, including during two FDA inspections of the Paterson facility.

In addition to the activities at Congers, some raw ingredients were shipped to the Paterson facility, Ahmad brought some products manufactured at ADH to the Paterson facility to be shipped to customers, and Ahmad loaded two pallets of product from the Paterson facility to a truck owned by Performance Food Centers. The Government alleged that these actions also violated the Consent Decree, and Appellants asserted a good faith defense to these charges as well.

Appellants were convicted of criminal contempt. Mohamed was sentenced to 40 months’ imprisonment. Ahmad and Omar were each sentenced to 34 months’ imprisonment, and the companies were fined. All appeal. 1

II. Discussion

Appellants raise four challenges to their convictions and one to a sentencing enhancement applied to Omar and Ahmad Desoky.

A. Exclusion of Mary Richardson’s Testimony

The District Court excluded Appellants’ offered testimony of Mary Richardson, an expert consultant they hired to help them comply with the FDA’s requirements in order to avoid and then lift the production shut-down. Richardson would not have testified about the charged conduct. Instead, her testimony related solely to Appellants’ efforts to remediate the issues identified at the Paterson facility.

We review a district court’s decision to admit evidence for abuse of discretion. *240 United States v. Givan, 320 F.3d 452, 460 (3d Cir.2003). Some evidence of earlier “good acts” evidence may be admissible to show a defendant lacked wrongful intent in later behavior. See United States v. Garvin, 565 F.2d 519, 522 (8th Cir.1977) (evidence of correctly submitted applications for approximately 18 insurance policies admissible to show lack of intent to commit a scheme to defraud); United States v. Shavin, 287 F.2d 647, 654 (7th Cir.1961) (evidence of properly submitted medical bills admissible to show lack of intent to defraud with later medical bills).

But Richardson’s testimony is not of this sort. Evidence that Appellants undertook ameliorative efforts at Paterson does not negate the Government’s theory — apparently adopted by the jury — that Appellants engaged in simultaneous efforts to improve the Paterson plant and to continue manufacturing elsewhere, with the latter actions violating the Consent Decree.

In addition, Richardson’s testimony would have raised ancillary issues about the initial problems at Paterson and the Appellants’ ameliorative efforts. The District Court concluded this outweighed any potentially probative value of the testimony. We agree, and, moreover, discern no harm in excluding Richardson’s testimony. United States v. Berrios, 676 F.3d 118, 131 (3d Cir.2012). Appellants provided uncon-tradicted evidence at trial about their efforts at Paterson, and their counsel were able to argue to the jury that these efforts demonstrated their lack of willfulness to violate the decree. In this context, the District Court did not err in excluding the testimony.

B. Jury Instruction on a Good Faith Defense

Appellants also challenge two aspects of the jury charge on their good faith defense. They argue that the Court improperly instructed the jury: (1) that an honest misunderstanding of the order must be plausible; and (2) that a defendant does not act in good faith if he also knowingly made false statements, representations, or purposeful omissions. The first part we review de novo because Appellants objected to the language at trial. United States v. Berrios, 676 F.3d at 136. Appellants contend that we should review the false statements instructions de novo

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Doreen Hendrickson
822 F.3d 812 (Sixth Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
512 F. App'x 237, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-quality-formulation-laboratories-inc-ca3-2013.